UK markets closed
NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
79.17 +0.18 (+0.23%) GOLD FUTURES
2,316.60 -5.70 (-0.25%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,047.68 -1,382.95 (-2.74%)
Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
At close: 12:59PM CEST
| Previous close | 280.80 |
| Open | 280.80 |
| Bid | 283.00 x 0 |
| Ask | 283.40 x 0 |
| Day's range | 280.00 - 285.60 |
| 52-week range | 189.03 - 302.00 |
| Volume | |
| Avg. volume | 534,362 |
| Market cap | 96.387B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 44.87 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Sobi has completed SEK 3 billion senior bond issue
Swedish Orphan Biovitrum AB (publ) (Sobi®) has successfully completed the inaugural issue of senior unsecured bonds of SEK 3 billion under its newly established MTN programme.
- PR Newswire
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
- PR Newswire
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
© 2024 Yahoo. All rights reserved.